Hernández HJM

Language: Spanish
References: 45
Page: 53-58
PDF size: 38.76 Kb.

ABSTRACT

Diabetes Mellitus is a world wide chronic disease that has taken the attention of many physicians and patients. More and better kind of treatments needs to be accessed. The Glitazones brings stability in the pancreatic beta-cellular function and decreases the insuline resistance level. Specific medical indications on Diabetic patients type 2 and their tberapeutic safety measures are now available in Costa Rica.

REFERENCES

1. Abrahansom M, Clincal use of thiazolidinediones: recomendations. Am Jour Med. 2003;115(Suppl 8A):1-6..

2. Anda E, Azparren A. Antidiabéticos orales. Boletín de Información Farmacoterapéutica de Navarra1999; 7(Num 1)

3. Arguedas J. Nateglinida. Actualización en Farmacoterapia. Actualización Médica Periódica. 2003; 25: 1-3.

4. Arguedas J. Tiazolidinedionas. Actualización en Farmacoterapia. Actualización Médica Periódica. 2002; 2: 1-3.

5. Arguedas J. Standars of Medical Care in Diabetes. Actualización Médica Periódica. 2004; 33: 1-9.

6. Arguedas J. Sulfonilureas. Actualización en Farmacoterapia. Actualización Médica Periódica. 2004; 33: 1-6.

7. Artiola S. Optimización del tratamiento de la diabetes tipo 2: ajustar el tratamiento al paciente y a la enfermedad. Reflexiones en medicina de familia. Atención Primaria 2003;31(2): 109-13

8. Balfour J, Plosker G. Rosiglitazone. Drugs 1999; 57: 921-30

9. BelI D, MB FACE, FACP. Beta-cell rejuvenation with thiazolidinediones. American Journal of Medicine. 2003;15(Suppl 8A).

10. Brown D y Jackson T. Diabetes tigh control in a comprehensive treatment plan. Geriatrics. 1994; 49: 24-31.

11. Browne D, Averyt L, Turner D, Kerr D y Cavan. What do patients with diabetes know about their tablets? Diabetes UK. Diabetic Medicine 2000; 17: 528-31.

12. Carretero M. Tratamiento de la Diabetes tipo 2. En: Actualidad Científica. OFFARM. 2002; 21(1): 127-31

13. Costa B, Nuevos enfoques terapeúticos en la Diabetes tipo 2. Medicina Clínica. 2001;117(4):137-141.

14. Couper J. Y Prins J. Recent advances in tberapy of diabetes. MJA. 2003;179(8): 441-447.

15. Czoski-Murray C, Warren E, Chilcot J, Beverly C, Psylaki M y Cowan J. The clinical cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes. National Institute for Clinical Excellence. Disponibte en: http://www.nice.org.uk/search.aspx-?seareh-mode=simple&ss=costeffectiveness.Accesado el 25 de Agosto del 2004.

16. Durruty P y garcía M. Glucotoxicidad y Iipotoxicidad: factores en la patogénesis y evolución de la diabetes tipo 2. Rev. Med. Chile. 2001;129(Num.6).

17. Evans J. Donnan P, y Morris D. Adherence to oral hypoglycaemic agents prior to insulin therapy in type 2 diabetes. Diabetes UK. Diabetic Medicine. 2002;19:685-8.

18. Fernández I. Novedades en el tratamiento con antidiabéticos orales. FMC 2002; 9(7): 471-80.

19. Fonseca V. Effect of Thiazolidinediones on body weight in patients with diabetes mellitus. American Journal of Medicine. 2003;115(Suppl 8A).

20. Freijanes J, Flores J. Insulina e hipoglucemiantes orales, Glucagón. En: Flóres J, Armijo J. Mediavilla A. Farmacología Humana. Segunda Edición, 1998. Editorial Masson. Cap 54; 935-942.

21. Gale E, Lessons from the glitazones: a story of drug development. Lancet. 2001; 357: lssue 9271 treatment of type 2 diabetes. National Institute for Clinical Excellence. Technology Appraisal 63. August 2003

22. Inzucchi S. Oral Antihyperglycemic therapy for type 2 diabetes. JAMA 2002; 16:360-72.

23. Islas S, Lifshitz A. Diabetes Mellitus. Primera Edición. México: Editorial Interamericana, Mc Graw-Hill; 1993

24. Khan M, Peter J, Xue J. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care. 2002; 25: 708-11.

25. King H, Aubert R, Herman W. Global burden of diabetes 1995-2005. Prevalence, numerical estimates, and projections. Diabetes Cure 1998; 21: 1414-31

26. Lebovitz H. Rationales for and role of thiazolidinediones in the type 2 diabetes mellitus. The American Journal of Cardiology. 2001;90(Num 5).

27. Levobitz H, Dole J, Patwardhan R, Rappapon E y Freed M. Rosiglitazone monotherapy is effctive in patients with type 2 diabetes. Jour Clin End Metab. 2001; 86(1): 1-14.

28. Llanes T. Nuevas evidencias en el manejo de la Diabetes Mellitus tipo 2. Mediffam 2002; 12

29. Mata M, Cos X, Pujol E, Bobé I, Centelles R, Ortiz R, et al. ¿Adelantan el diagnóstico de la diabetes tipo 2 los nuevos criterios de la Asociación Americana de Diabetes?. Atención Primaria 2001; 28: 17-22.

30. Mayerson A, Hundal R, Dufour S, Lebon V, Befroy D, Cline G, et al. The effects of Rosiglitazone on Insulin Sensitivity, lipolysis and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes. 2002;51: 797-802.

31. Miyazaki Y, Mahankali A, Matsuda M, Gras L, Mahankalis S, Ferrannini E, et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care. 2001; 24:710-9

32. Mycek M, Harvey R y Charpe P. Pharmacology. Lippincourt Illustrated Review. Editorial Lippincott Williams and Wilkins. Segunda Edición 2000. Cap 26:260-1.

33. NICE updates guidance on glitazone for people with type 2 diabetes in England and Wales. National Institute for Clinical Excelence. August 2003. Disponible en www.nice.org.uk. Accesado12 de agosto del 2004.

34. Pavo I, Jermendy G, Varkonyi T, Kerenyi Z, Gyimesi A, Shoustov S, et al. Effect of pio- glitazone compared with metfomin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with 2 diabetes. J Clin EndocrinolMetab. 2003; 88(4):1637-45

35. Purnel J, Hirsch I. New Oral Therapies for type 2 diabetes. American Family Phisician 1997; 56( Issue 7).

36. Rosello-Araya M. Prevalencia de diabetes tipo 2, intolerancia a la glucosa y diabetes provisional en El Guarco, Cartago. Rev Costarric Cienc Med 2003; 24: 1-12.

37. Ross S, Zinman B, Campos R, Strack T. Canadian Lispro Study Group. A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secundary failure of oral hypoglycemie agents. Clin Invest Med. 2001; 24(6): 292-8.

38. Sistema Nacional de Vigilancia de la Salud de Costa Rica. Boletín Epidemiológico. 2003;3(No 37).

39. Sean C Sweetman. Parte1: Antidiabéticos. In: Pharma Editores. Martindale Guía Completa de Consulta Farmacoterapéutica, SL. Pharma Editores; 2003: 439-463.

40. Stahl M and berger W. Higher incidence of severe hypoglycaemia leading to hospital admission in type 2 diabetic patients treated with long-acting versus short.acting sulphonylureas. British Diabetic Association. Diabetic Medicine,16, 586-90.

41. The DECODE study group on behalf of the European Diabetes Epidemiology group. Glucose tolerance and mortality: comparison of WHO and American Diabetic Association Diagnostic criteria. Lancet 1999; 354:617-21.

42. Torrecilla M, Ríos C, Fernández I. Prevalencia de diabetes tratada con fármacos en Andalucía. Evolución de la prescripción de antidiabéticos orales e insulina entre 1994 y 2000. Rey Clin Esp 2003; 203(9): 426-9.

43. Tratamiento Farmacológico Capítulo 7. En las Guías ALAD para el Diagnóstico y Manejo de la Diabetes Mellitus tipo 2 Con Medicina Basada en la Evidencia. Rev. Asoc Latinoam Diab. 2000; (Suppl 1),

44. Turner C, CulI C, Frighi V, Holman R. The UKPDS. Glycemic control with diet, sulfonylureas, metformin or insulin in patienes with type 2 diabetes melliuts. JAMA. 1999;281(Num21):2005-12.

45. UK Prospective Diabetes Study (UPKDS) Group. Intensive blood-glucose control with sulphonilureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. (UKPDS 33). Lancet 1998; 352: 837-53.